Rizzo Alessandro
Struttura Semplice Dipartimentale di Oncologia Medica per la Presa in Carico Globale del Paziente Oncologico "Don Tonino Bello", I.R.C.C.S. Istituto Tumori "Giovanni Paolo II", Viale Orazio Flacco 65, 70124 Bari, Italy.
J Clin Med. 2022 Jul 5;11(13):3912. doi: 10.3390/jcm11133912.
Since endometrial cancers (ECs) are frequently TMB-H and MSI-H/dMMR tumors, this element has provided the rationale for testing immune checkpoint inhibitors (ICIs), which have recently emerged as a potential game-changer. However, several questions remain to be addressed, including the identification of patients who may benefit from the addition of ICIs as well as those who do not need immunotherapy. In the current paper, we provide an overview of the clinical development of immunotherapy in advanced or recurrent EC, discussing the role of MMR and the "elective affinities" between ICIs and this predictive biomarker in this setting.
由于子宫内膜癌（ECs）通常是肿瘤突变负荷高（TMB-H）和微卫星高度不稳定/错配修复缺陷（MSI-H/dMMR）的肿瘤，这一因素为检测免疫检查点抑制剂（ICIs）提供了理论依据，而免疫检查点抑制剂最近已成为一种潜在的变革性药物。然而，仍有几个问题有待解决，包括确定哪些患者可能从添加ICIs中获益以及哪些患者不需要免疫治疗。在本文中，我们概述了晚期或复发性EC免疫治疗的临床进展，讨论了错配修复（MMR）的作用以及ICIs与这种预测性生物标志物在这种情况下的“选择性亲和力”。
